Celltrion formed Vcell Healthcare Limited with Nan Fung Group with the aim of commercializing 3 biosimilars in China.
Celltrion said this week it created a joint venture company in order to pursue the commercialization of 3 biosimilars in China.
Celltrion formed Vcell Healthcare Limited with Nan Fung Group; Vcell also signed a licensing agreement with Celltrion.
Vcell will obtain the exclusive rights in mainland China to develop, manufacture and commercialize 3 biosimilar products from Celltrion: CT-P13 (Remsima, Inflectra, an infliximab product referencing Remicade), CT-P10 (Truxima, a rituximab product referencing Rituxan) and CT-P6 (Herzuma, a trastuzumab product referencing Herceptin).
In addition, Celltrion and Nan Fung Group will explore the opportunity to develop a biologics manufacturing facility in China.
CT-P13, approved in the European Union and the United States is sold in more than 80 countries worldwide. Truxima is also approved in the United States and in Europe; Herzuma carries those approvals as well as approvals in Japan.
Vcell aims to launch the products quickly after following China’s regulatory approval process. If approved, the 3 would join the 1 other approved biosimilar in China, a biosimilar rituximab approved in February 2019 (Henlius’ HLX01). Approval of this rituximab product was a milestone for the Chinese market, as it was not only the first rituximab biosimilar to be approved in the market, but also the first biosimilar to be cleared under the country’s biosimilar approval pathway.
Executives from the 2 companies were enthusiastic about the announcement.
"We are extremely excited about the establishment of Vcell Healthcare Limited, which will serve as the cornerstone for our entry into the Chinese market,” said Seo Jung-Jin, Celltrion’s chairman, in a statement. “We will make our best efforts to start business in China as soon as possible and provide Chinese patients with our outstanding biosimilar products which have already been approved in the global markets such as the US, Europe, and South Korea."
"China has huge unmet medical needs for high quality drugs with affordable prices,” added Antony Leung, chairman and chief executive officer Nan Fung. “We hope Vcell Healthcare Limited could bring world-class biosimilar products to benefit Chinese patients and establish a state-of-the-art manufacturing base in China to serve growing demand for high quality CDMO in the country."
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.